



iFabric 
CORPORATION

INVESTOR PRESENTATION JULY 2020

WE ARE DEDICATED TO SOCIALLY
RESPONSIBLE TECHNOLOGIES THAT
IMPROVE THE WEARER'S EXPERIENCE

TSX: IFA; OTC: IFABF

DISCLAIMER

Information provided on the website of iFabric Corporation (the “Company”) including the reports posted thereto contains forward-looking statements that reflect management’s current expectations relating to matters such as future financial performance and operating results of the Company.

Forward-looking statements are provided for the purpose of providing information about management’s current expectations and plans, and allow investors and others to better understand the Company’s anticipated financial position, results of operations and operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

Certain statements may constitute forward-looking statements, including but not limited to, statements regarding the expected benefits and results of the Company’s initiatives and other statements concerning management’s current expectations relating to possible or assumed future prospects and results, the Company’s strategic goals and priorities, its actions and the results of those actions and the economic and business outlook for the Company. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “believe”, “estimate”, “plan”, “can”, “could”, “should”, “would”, “outlook”, “forecast”, “anticipate”, “aspire”, “foresee”, “continue”, “ongoing” or the negative of these terms or variations of them or similar terminology. Forward-looking statements are based on the reasonable assumptions, estimates, analyses, beliefs and opinions of management, made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable at the date that such statements are made.

By their very nature, forward-looking statements require management to make assumptions and are subject to inherent risks and uncertainties, which give rise to the possibility that the Company’s assumptions, estimates, analyses, beliefs and opinions may not be correct and that the Company’s expectations and plans will not be achieved. Although the Company believes that the forward-looking information in the statements are based on information, assumptions and beliefs that are current, reasonable and complete, such information is necessarily subject to a number of factors that could cause actual results to differ materially from management’s expectations and plans as set forth in such forward-looking statements. Some of the factors, many of which are beyond the Company’s control and the effects of which can be difficult to predict, include but are not limited to, changes in economic and market conditions and other risks and uncertainties discussed in the Company’s materials filed with the Canadian securities regulatory authorities from time to time as well as the Company’s other public filings, available on the SEDAR (System for Electronic Document Analysis and Retrieval) website at www.sedar.com. Management cautions that the foregoing list of important factors and assumptions are not exhaustive and other factors could also adversely affect the Company’s initiatives.

Investors and other readers are urged to consider the foregoing risks, uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements and information contained in the Reporting are based on certain factors and assumptions as of the date hereof. The Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by it or on its behalf, to reflect new information, future events or otherwise, except as is required by applicable securities laws.

COMPANY HIGHLIGHTS

INTELLIGENT FABRICS THAT ADDRESS UNMET CONSUMER AND MEDICAL NEEDS

- ▶ Patented antimicrobial technologies for performance apparel
- ▶ **Antiviral treatment solution has been 3rd party tested against COVID-19 and several other viruses and bacteria**
- ▶ Sustainable water repellent, moisture wicking and UV protection technologies

ADVANCED CLAIM US EPA APPROVAL WILL BE MAJOR CATALYST

- ▶ Pending additional US EPA claim registration for our anti-viral technology would create a step change in demand with current customers and new clients

GLOBAL PANDEMIC - NEW CONSUMER TRENDS CREATE MASSIVE UPSIDE POTENTIAL

- ▶ \$9M annualized revenue run rate does not reflect pipeline for intelligent fabric technologies

MAJOR BRAND PARTNERSHIPS

- ▶ Under Armour, Charismatic Brands, Lululemon, Walmart, Target, and The North Face are among our current top brands partners

MANAGEMENT ALIGNED

- ▶ Management ownership is 75%+ of the Company

MANAGEMENT



HYLTON KARON
President & CEO

Graduated from Philadelphia University with a BSC degree in textile marketing and management, and now has over 35 years of experience in product development and marketing. Hylton's creative ability has resulted in the development of many successful and patented products which are sold both in North America and internationally.



GIANCARLO BEEVIS
President & CEO | IFTNA

A graduate with an Honours B.A. from York University, Giancarlo has been involved with the company for 15 years, contributing expert knowledge and is instrumental in the brand development of Intelligent Fabric Technologies North America. Giancarlo oversees the strategic direction of IFTNA and the development of products, brands and technologies.



HILTON PRICE
Group Chief Financial Officer

A Chartered Professional Accountant with over 40 years of experience covering a variety of industries and business. Hilton has been involved in most elements of the group's strategic planning and is responsible for financial oversight since the groups inception.



JASON GARAY
Chief Science Officer | IFTNA

Mr. Garay is VP Analytics and Informatics at Cancer Care Ontario (CCO). Jason was previously the Director, Communicable Disease Prevention and Control at Public Health Ontario. He is an Adjunct Professor at the University of Toronto and holds an MHSc in Community Health and Epidemiology, a BASc in Occupational and Public Health, and a BSc (Honours) in Statistics and Psychology.

BOARD OF DIRECTORS

Dr. Mark Cochran

PhD
Chairman

Dr. Cochran is Executive Director of Johns Hopkins Medicine. His experience spans all levels of the drug discovery and development value chain, including operational and executive roles in the healthcare, venture capital, pharmaceutical, and biotech industries.

Mark Greenspan

CA, CBV
Director

Mr. Greenspan was CFO of The Medipattern Corporation from September 2002 until February 2010. Prior to that, he spent 18 years at Scotiabank in various executive capacities. Prior to joining Scotiabank, he spent 8 years at KPMG where he specialized in mergers and acquisitions.

Cameron Groome

Director

Cameron has served on the MBX Board of Directors and Advisory Committee since 2012, and was appointed CEO in 2017. He has more than 25 years' experience in senior life sciences and finances roles and has been an executive, director, and advisor for public and private companies.

Hylton Karon

Director

Mr. Karon is the President and CEO of iFabric Corp.

Hilton Price

Director

Mr. Price is the CFO of iFabric Corp.

Giancarlo Beevis

Director

Mr. Beevis is the President and CEO of IFTNA, a division of iFabric Corp.

CAPITAL STRUCTURE

TSX LISTED, SYMBOL: IFA OTC: IFABF

iFabric Corp. (IFA.TO) ☆

Toronto - Toronto Delayed Price. Currency in CAD

5.12 -0.17 (-3.21%)

At close: 3:58PM EDT



Current Price	\$5.12	Market Capitalization	\$135.2M
Shares Outstanding (Basic)	26.2M	Avg. Daily Volume (last 12 months)	9,072
(Fully Diluted)	28.2M	Available Cash and Line of Credit	\$6.0M
52 Week High	\$7.87	Long Term Debt	\$1.3M
52 Week Low	\$0.52	Management Ownership	>75%

TWO DIVISIONS

Socially responsible fabric technologies as well as intimates and wardrobe solutions.



INTELLIGENT FABRIC TECHNOLOGIES (NORTH AMERICA) INC. (IFTNA)

- ▶ **Revenue Stream #1** Developed a range of performance additives for textiles. Including antimicrobial and antiviral textiles and solutions for medical, athletic, military, consumer & corporate apparel, bedding, linens and other categories.
- ▶ Lab testing has confirmed the PROTX2 solution is efficacious against COVID-19, Coronavirus, MRSA, Staph, C-Diff, VRE, E. Coli, Norovirus, H1N1, and Influenza A & B
- ▶ **Revenue Stream #2** Manufacturing private label performance apparel utilizing key technologies
- ▶ **Revenue Stream #3** Launching own brand of performance and travel apparel as well as own brand of personal protective equipment in the near term



COCONUT GROVE INTIMATES

- ▶ Coconut Grove Intimates is where high-style and comfort meets design and functionality. Over the last 35 years, our team of designers have been developing and supplying the fashion industry with unique and superior intimate and sleepwear apparel collections that reach global markets. Since our inception, we have developed many utility and design patents setting our offering apart from the rest.

IFTNA TECHNOLOGY PORTFOLIO

IFTNA has developed a number of products that are partnered with household brands:

- PROTX2®** antimicrobial, antiviral, and anti-odour
- REPEL^{TX} ECO PLUS** fluorine free water repellent
- OMEGA+** Infrared technology
- TEMP-X** Thermo regulator
- ECOT^{TX}** Metal-free antimicrobial
- DREAMSKIN** hydration technology
- APOLLO** Body odour neutralizer

- DRYFORCE** Evaporation Enhancement
- ENGUARD** Insect Repellent
- DRY^{TX}** Moisture wicking technology
- UV^{TX}** UV protection
- imPRINT** Wicks away moisture using fabric gateways exposing logos and patterns



IFTNA BRAND PARTNERSHIPS



THE PROBLEM

A GLOBAL PANDEMIC

- ▶ Amid the COVID-19 crisis, the global market for **Antimicrobial Textiles estimated at US\$8.5 Billion in the year 2020, is projected to reach a revised size of US\$11.5 Billion by 2027**
- ▶ The U. S. Accounts for Over **29.4% of Global Market Size in 2020, While China is Forecast to Grow at a 4.2% CAGR for the Period of 2020-2027**

HEALTHCARE ASSOCIATED INFECTIONS (HAI'S)

- ▶ Now one of the top 6 leading causes of deaths in the developed world (CDC, NIH)
- ▶ Textiles are a major source of HAI-causing pathogens and yet there is no effective way to keep them free of these pathogens during use
- ▶ **60% of standard medical uniforms are contaminated with up to 4 potentially infectious bacteria**
- ▶ **92% of hospital privacy curtains are contaminated** with multiple infectious bacteria
- ▶ **100,000 deaths** from hospital HAI's last year

CONSUMER DESIRE

- ▶ The consumer desire for sustainable controlled odour solutions that allow for more wear and less washing



Bacteria can easily survive the average drying cycle of 28 minutes and can live on fabric for up to 2-3 weeks

PROTX2®

THE BREAKTHROUGH

PROTX2® is a breakthrough in antimicrobial and antiviral protection. When treated, each fiber is fundamentally transformed through PROTX2®'s technology providing proprietary unrivalled protection.

PROTX2® in different dosages can be used in two distinct ways:

1 **HEALTHCARE, HOSPITALITY & FOOD SERVICE**

as an **antimicrobial, antibacterial, and antiviral** agent

2 **SPORTSWEAR**

as an **anti-odour** agent



PROTX2®

ANTIMICROBIAL, ANTIBACTERIAL, ANTIVIRAL AGENT

- ▶ PROTX2® is the world's first antiviral textile technology proven to kill greater than 99.9% of SARS-COV-2 (COVID-19) in 10 minutes
- ▶ An effective, medical-grade solution for reducing the spread of nosocomial infections on soft and hard surfaces.
- ▶ **PROTX2® will be the world's first antimicrobial/antiviral technology to be registered for kill claims with the US EPA.**
- ▶ It is 3rd party certified by independent laboratories to be an incredibly effective broad spectrum antibacterial and antiviral technology.
- ▶ Our recent lab testing has shown PROTX2®'s efficacy against COVID-19 and Coronavirus and has been tested against MRSA, Staph, C-Diff, VRE, E. Coli, Norovirus, H1N1, and Influenza A & B.
- ▶ 2 Clinical trials pending start in California: 400 nurses wearing PROTX2® treated scrubs, swabbed before and after shifts.
- ▶ The PROTX2® solution is already in use by one of the largest Scrub Manufacturers in the United States



PRIVATE BRAND LAUNCHES



Underit® is IFTNA's privately owned brand, that specializes in developing forward thinking technology infused performance and travel apparel, with PROTX2® as the host of all our other technologies.

We have designed, developed and patented an extensive range of mens, womens, and kids products listed below:


**Underwear | Sports Bras | Base Layer | Tights/
Leggings | Shirts & Tops | Compression |
Athleisure**

For launch year we have an expected revenue of \$5M with a 20-25% margin. Year 2 is an expected \$10M in revenues with 40-55% margin.



Frontline® is another IFTNA privately owned brand, specializing in PROTX2® AV treated personal protective equipment such as:

Masks | Gloves | Gowns | Other Necessary PPE



MARKET OPPORTUNITIES

INTELLIGENT FABRIC TECHNOLOGIES



OPPORTUNITY

ADDRESSABLE MARKET

APPLICATIONS

PERFORMANCE APPAREL

1. Supply of performance chemicals into global brand supply chain
2. Design manufacturing supply of finished product performance apparel under private label
3. Design manufacturing supply of finished product performance apparel under license
4. Launch of own brand and travel apparel (Underit)

TOTAL MARKET SIZE: \$106+ Billion¹

1. \$2 Billion (**Margin** 35%)
2. \$4 Billion (**Margin** 40-50%)
3. \$200 Million (**Margin** 40%)
4. \$1 Billion (**Margin** 50+%)

- *Underwear
- *Base Layer
- *Golf Shirts
- *T-Shirts
- *Sports Bras
- *Shorts
- *Pants
- *Gloves

MEDICAL APPAREL

1. Supply of performance chemicals into medical market leader supply chains
2. Design manufacturing supply of owned brand personal protective equipment and medical devices

TOTAL MARKET SIZE: \$10+ Billion²

1. \$4 Billion (**Margin** 45%)
2. \$4 Billion (**Margin** 45%)

- *Scrubs
- *Surgical Gowns
- *Patient Gowns
- *Surgical Gloves
- *Masks

MEDICAL AND HOME TEXTILES

1. Supply of performance chemicals into market leader supply chains
2. Design manufacturing supply of finished home textile products

TOTAL MARKET SIZE: \$10+ Billion³

1. \$500 Million (**Margin** 45%)
2. \$500 Million (**Margin** 45%)

- *Bedding
- *Privacy Curtains
- *Upholstery
- *Carpeting
- *Air Filtration

¹The worldwide market for performance apparel is expected to grow at a CAGR of roughly 9.5% over the next five years and will reach \$10,600 million US\$ in 2024 from \$6,140 million US\$ in 2019, according to the latest GIR (Global Info Research) study.

²Scrubs are a \$10 billion industry in the United States and \$60 billion worldwide. Thousands of medical professionals enter the workforce every year.

³According to a new report by Zion Market Research, the global medical textile business is shifting towards smart healthcare textile products in clinics, hospitals, homes, hotels etc...with the value of the global healthcare fabrics market amounting to USD \$10.1 billion in 2018 and is expected to generate around USD \$15.7 billion by 2025 at a CAGR of around 6.5%.

COCONUT GROVE INTIMATES



Over the last 30 years, we have continued to stay on top of market trends to design, develop and supply the fashion industry with unique solution bras and bra accessories for every possible occasion. CGI is part of a niche market with aging competition and room for exponential growth.



25+ YEARS OF PROFITABILITY

Over 25 years of profitable operations with gross margins over 50%.






PRIVATE LABEL

Distribution across Canada, USA and the UK with over 1,000 different product offerings.



PATENTS

Innovative new patents in the near term



BRANDS



PRIVATE LABEL


FLAGSHIP RETAILERS



FINANCIALS AND PROJECTIONS

IFABRIC GROUP


MILLIONS



2018: \$15.1 M
2019: \$10.4 M
2020: \$12 M
2021: \$29 M
2022: \$56 M
2023: \$78 M

IF TECHNOLOGIES NA


MILLIONS



2020: \$9 M
2021: \$25 M
2022: \$50 M
2023: \$70 M

COCONUT GROVE INTIMATES

MILLIONS



2020: \$3M
2021: \$4 M
2022: \$6 M
2023: \$8 M

HISTORIC EARNINGS

IFABRIC GROUP

	2018	2019
Revenue	15,121,370	10,435,348
Adjusted EBITDA*	1,783,260	-1,339,227
Net Earnings (Loss per share)		
Basic	0.035	-0.05
Diluted	0.034	-0.05

*Adjusted EBITDA represents earnings before interest, taxes, depreciation, amortization and share based compensation.
 Reduction in revenues from 2019 to 2018 is attributable to the elimination of sleepwear sales in the Intimate Apparel Division

UPCOMING MILESTONES

US EPA ADVANCED CLAIM REGISTRATION

Kill claim registrations
are imminent

CLINICAL TRIALS WITH PROTX2® & REPELTIX®

2 trials pending with 400
nurses in 2 major US hospital
systems utilizing PROTX2® and
RepelTX® technologies

OWNED BRAND LAUNCH - UNDERIT® & FRONTLINE®

Underit® travel and performance
apparel line expected to launch
Spring 2021

Frontline® personal protective
equipment brand expected to
launch Q4 2020-Q1 2021

EXPANDING CUSTOMER BASE AND RENEWED CUSTOMERS

Large pipeline of new customers
and indications of reorders from
clients

APPENDIX

PATENT PORTFOLIO

Our portfolio of innovative patents answer today's market trends.

PATENT PENDING

PROTX2 AVGuard

Our proprietary laundry additive with antimicrobial, antibacterial and antiviral properties.

PROTX2® AVGuard
DUO POWER

PATENT PENDING

PROTX2 AV


Our antimicrobial, antibacterial and antiviral agent.

PROTX2®
AV
ANTIMICROBIAL
TECHNOLOGY

PATENT PENDING

MESH SLING

Using the most advanced construction techniques and materials, we've created a mesh sling that provides optimum support and comfort.



PATENT PENDING


2-SIDED FLY

Our 2-sided patented fly design caters to the wearer's needs, whether they are left or right handed, while providing all day comfort and support.



PATENT PENDING SLOTTED MASK

Triple layer constructed protective mask.



PATENT PENDING HAT MASK

A protective mask designed with a clip feature to attach to hats.



PATENTED BREAST LIFT

The perfect braless solution with a unique tab design providing customizable lift and a contoured natural shape.



PATENT PENDING REVERSIBLE WING BRA

1 bra with 2 colour choices (nude and black) designed with double-sided silicone wings and dyed to match wing covers.



IN THE MEDIA

FAST COMPANY




BY SUSAN KARLIN 6 MINUTE READ

The call came at 3:30 a.m. "Does your stuff work on COVID?"

Giancarlo Beevis sighed. He had been pulling his hair out trying to lock down a specialty lab that could test his antiviral fabric treatment's ability to deactivate the SARS-CoV-2 virus. "We'd searched everywhere for anyone who could test for COVID, specifically," said Beevis, who is the CEO of the Canadian biotech firm [Intelligent Fabric Technologies North America \(IFTNA\)](#). "We weren't interested in testing it against the human coronavirus, which our competitors were doing, because to us it didn't have value. We wanted to deal with the pandemic."


[Full Fast Company Article](#)

FORBES



[Full Forbes Article](#)
[Underarmour Website](#)

ZOZO (JAPAN)



PROTX2 AV is a chemical used as a coating in the production stage of fabrics, and it is expected to be used as an infection prevention tool that can be easily introduced, not as a means to kill the source of infection. This time, we interviewed Giancarlo Beevis, CEO of "[Intelligent Fabrics Technologies \(also known as IFTNA\)](#)", who developed PROTX2 AV, regarding the research background and future prospects of PROTX2 AV. ...



[Full Zozo Article](#)

UPCOMING FEATURES: [CTV NEWS](#) | [EVERYDAY HEALTH](#) | [CEOCFOINTERVIEWS.COM](#)





THANK YOU!








HYLTON KARON

 President & CEO
 hyltonk@ifabriccorp.com
 905.752.0566 x201
 905.752.0567

HILTON PRICE

 Chief Financial Officer
 hilton.price@rogers.com
 647.465.6161
 905.752.0567

GIANCARLO BEEVIS

 President & CEO | IFTNA
 GC@iftna.com
 647.225.4426
 905.752.0566 x202
 905.752.0567

INVESTOR RELATIONS:

TINA BYERS

905.330.3275
tina@adcap.ca

JEAN-FRANCOIS DUBÉ (QUEBEC)

514.233.9551
jfdube@mac.com

GARY PERKINS

418.882.0020
garyperkins@rogers.com